New combo therapy aims to stop brain cancer growth in older patients

NCT ID NCT05998642

Recruiting now Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the combination therapy. The main goal is to see if the cancer stays under control for at least one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Allan Blair Cancer Centre
RECRUITING

Regina, Saskatchewan, S4T 7T1, Canada
Arthur J.E. Child Comprehensive Cancer Centre
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
BCCA - Vancouver
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)
RECRUITING

Québec, Quebec, G1J 1Z4, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
RECRUITING

Hamilton, Ontario, L8V 5C2, Canada
Ottawa Hospital Research Institute
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
The Research Institute of the McGill University
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
University Health Network
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.